Background One of the most malignant tumors in men is prostate cancer that is still incurable
due to its heterogenous and progressive natures. Genetic and epigenetic changes play …

Prostate cancer is the most commonly diagnosed cancer affecting men in the United States.
The prostate is a hormone-dependent gland in which androgen hormones testosterone and …

The determination of molecular features that mediate clinically aggressive phenotypes in
prostate cancer remains a major biological and clinical challenge,. Recent advances in …

Prostate cancer is the most frequent nonskin cancer and second most common cause of
cancer-related deaths in man. Prostate cancer is a clinically heterogeneous disease with …

Evolutionarily conserved Notch plays a critical role in embryonic development and cellular
self-renewal. It has both tumour suppressor and oncogenic activity, the latter of which is …

Prostate cancer is the second most common malignancy in men and androgen deprivation
therapy is the first‐line therapy. However, most cases will eventually develop castration …

The functional consequences of genetic variants within 5'untranslated regions (UTRs) on a
genome-wide scale are poorly understood in disease. Here we develop a high-throughput …

The new generation androgen receptor (AR) pathway inhibitor enzalutamide can prolong
the survival of patients with metastatic prostate cancer. However, resistance to enzalutamide …

Currently, chemotherapy is the main treatment for tumors, but there are still problems such
as unsatisfactory chemotherapy results, susceptibility to drug resistance, and serious …

Drug resistance is still an obstacle in cancer therapy, leading to the failure of tumor
treatment. The emergence of tumor drug resistance has always been a main concern of …